Microlaryngoscopic and Office-Based Injection of Bevacizumab (Avastin) to Enhance 532-nm Pulsed KTP Laser Treatment of Glottal Papillomatosis
Authors:
- Gerardo Lopez-GuerraGLGerardo Lopez-Guerra
- James A. BurnsJBJames A. Burns
- Matthew LutchMLMatthew Lutch
- Aaron M. FriedmanAFAaron M. Friedman
- Robert E. HillmanRHRobert E. Hillman
- 1 September 2009
- journal article
- research article
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 118 (9) , 1-24
Abstract
Objectives: Photoangiolytic lasers effectively treat glottal papillomatosis, but do not reliably prevent recurrence. Therefore, sublesional injections of the antiangiogenic agent bevacizumab (Avastin) were given to assess the effect on disease recurrence and phonatory function. Methods: A retrospective investigation was done in a pilot group of 10 adult patients with bilateral glottal papillomatosis who had prior angiolytic laser treatment with established patterns of recurrence. The patients underwent 5 bevacizumab injections (5 to 10 mg) into the diseased vocal folds along with 532-nm pulsed KTP laser photoangiolysis treatments 4 to 6 weeks apart. Their disease resolution was compared to findings from prior laser treatment alone, and objective measures of vocal function (acoustic, aerodynamic, Voice-Related Quality of Life survey) were obtained. Results: All 10 patients had a greater than 90% reduction in recurrence. Four of the 10 had resolution. Four of the 10 have limited recurrent or persistent disease, receive injections of bevacizumab at 8- to 12-week intervals, and have not required laser treatment. Two of the 10 have ongoing periodic office-based KTP laser treatment along with bevacizumab injections. No patient has required microlaryngeal surgery with general anesthesia, and all 10 have had substantial improvement in vocal function. Conclusions: This pilot investigation provides preliminary evidence that bevacizumab injections enhance photoangiolytic laser treatment of glottal papillomatosis while enhancing phonatory function. Coupling an antiangiogenesis agent with pulsed KTP laser photoangiolysis is conceptually promising, since the mechanisms of action are complementary.Keywords
This publication has 44 references indexed in Scilit:
- Office-Based Treatment of Glottal Dysplasia and Papillomatosis with the 585-NM Pulsed Dye Laser and Local AnesthesiaAnnals of Otology, Rhinology & Laryngology, 2004
- Powered Instrumentation in the Treatment of Recurrent Respiratory PapillomatosisJAMA Otolaryngology–Head & Neck Surgery, 2002
- Flash Pump Dye Laser Treatment of Laryngeal PapillomasAnnals of Otology, Rhinology & Laryngology, 1998
- A 585‐nanometer pulsed dye laser treatment of laryngeal papillomas: Preliminary reportThe Laryngoscope, 1998
- Premalignant epithelium and microinvasive cancer of the vocal fold: The evolution of phonomicrosurgical managementThe Laryngoscope, 1995
- Selective Photothermolysis: Precise Microsurgery by Selective Absorption of Pulsed RadiationScience, 1983
- Microvasculature Can Be Selectively Damaged Using Dye Lasers: A Basic Theory and Experimental Evidence in Human SkinLasers in Surgery and Medicine, 1981
- Recurrent Respiratory PapillomatosisAnnals of Otology, Rhinology & Laryngology, 1976
- Laser Surgery in the Larynx Early Clinical Experience with Continuous Co 2 LaserAnnals of Otology, Rhinology & Laryngology, 1972
- Laser surgery of the vocal cordsAn experimental study with carbon dioxide lasers on dogsThe Laryngoscope, 1972